Bachem Holding AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH1176493729
CHF
66.90
-59.88 (-47.23%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Flat results in Jun 25

  • INTEREST(HY) At CHF 0.17 MM has Grown at 23.24%
  • DEBT-EQUITY RATIO (HY) Highest at 2.33 %
  • CASH AND EQV(HY) Lowest at CHF 29.14 MM
2

With ROE of 7.81%, it has a Very Expensive valuation with a 3.03 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 5,572 Million ()

stock-summary
P/E

39.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

114.40%

stock-summary
Debt Equity

0.02

stock-summary
Return on Equity

7.81%

stock-summary
Price to Book

4.10

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-47.23%
0%
-47.23%
6 Months
-47.23%
0%
-47.23%
1 Year
-47.23%
0%
-47.23%
2 Years
-47.23%
0%
-47.23%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Bachem Holding AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.73%
EBIT Growth (5y)
16.17%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.14
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.50
Tax Ratio
11.07%
Dividend Payout Ratio
53.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.44%
ROE (avg)
10.17%

Valuation key factors

Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
3.03
EV to EBIT
25.37
EV to EBITDA
20.45
EV to Capital Employed
2.98
EV to Sales
6.12
PEG Ratio
NA
Dividend Yield
154.83%
ROCE (Latest)
11.75%
ROE (Latest)
7.81%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Bachem Holding AG"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 8.58% vs 5.66% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 11.12% vs -12.21% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "577.30",
          "val2": "531.70",
          "chgp": "8.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "165.90",
          "val2": "159.60",
          "chgp": "3.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.70",
          "chgp": "-42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "111.90",
          "val2": "100.70",
          "chgp": "11.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "222.70%",
          "val2": "237.50%",
          "chgp": "-1.48%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'23stock-summary

Dec'23
Dec'22
Change(%)
Net Sales
577.30
531.70
8.58%
Operating Profit (PBDIT) excl Other Income
165.90
159.60
3.95%
Interest
0.40
0.70
-42.86%
Exceptional Items
3.60
0.00
Consolidate Net Profit
111.90
100.70
11.12%
Operating Profit Margin (Excl OI)
222.70%
237.50%
-1.48%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 8.58% vs 5.66% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 11.12% vs -12.21% in Dec 2022

stock-summaryCompany CV
About Bachem Holding AG stock-summary
stock-summary
Bachem Holding AG
Pharmaceuticals & Biotechnology
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Company Coordinates stock-summary
Company Details
Hauptstrasse 144 , BUBENDORF None : 4416
stock-summary
Tel: 41 61 9352333
stock-summary
Registrar Details